Merck & Co., Inc. (NYSE:MRK) Receives New Coverage from Analysts at Svb Leerink

Svb Leerink began coverage on shares of Merck & Co., Inc. (NYSE:MRK) in a research note published on Friday, BenzingaRatingsTable reports. The brokerage issued an outperform rating and a $103.00 price target on the stock. Svb Leerink also issued estimates for Merck & Co., Inc.’s Q3 2019 earnings at $1.24 EPS, Q4 2019 earnings at $1.17 EPS and FY2023 earnings at $6.33 EPS.

MRK has been the topic of several other research reports. Citigroup increased their price objective on Merck & Co., Inc. from $84.00 to $95.00 and gave the stock a buy rating in a research note on Friday, June 21st. They noted that the move was a valuation call. BMO Capital Markets increased their price objective on Merck & Co., Inc. from $83.00 to $84.00 and gave the stock a market perform rating in a research note on Wednesday, May 1st. Leerink Swann began coverage on Merck & Co., Inc. in a research report on Thursday. They set an outperform rating and a $103.00 target price on the stock. Bank of America set a $97.00 target price on Merck & Co., Inc. and gave the company a buy rating in a research report on Thursday, July 11th. Finally, Atlantic Securities raised Merck & Co., Inc. from a neutral rating to an overweight rating in a research report on Monday, May 13th. They noted that the move was a valuation call. Three research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. The company presently has a consensus rating of Buy and an average target price of $92.56.

NYSE:MRK traded up $1.60 during midday trading on Friday, hitting $85.06. The stock had a trading volume of 8,550,000 shares, compared to its average volume of 9,547,986. Merck & Co., Inc. has a one year low of $66.10 and a one year high of $87.07. The company has a market capitalization of $213.54 billion, a price-to-earnings ratio of 19.60, a PEG ratio of 1.70 and a beta of 0.56. The stock has a 50-day moving average of $83.38 and a 200 day moving average of $80.94. The company has a quick ratio of 0.92, a current ratio of 1.21 and a debt-to-equity ratio of 0.82.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings data on Tuesday, July 30th. The company reported $1.30 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.16 by $0.14. Merck & Co., Inc. had a return on equity of 43.34% and a net margin of 21.10%. The company had revenue of $11.76 billion for the quarter, compared to analysts’ expectations of $10.94 billion. During the same quarter in the prior year, the firm earned $1.06 earnings per share. Merck & Co., Inc.’s revenue was up 12.4% compared to the same quarter last year. On average, sell-side analysts anticipate that Merck & Co., Inc. will post 4.91 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, October 7th. Stockholders of record on Monday, September 16th will be issued a dividend of $0.55 per share. The ex-dividend date is Friday, September 13th. This represents a $2.20 annualized dividend and a dividend yield of 2.59%. Merck & Co., Inc.’s dividend payout ratio is presently 50.69%.

In other news, EVP Richard R. Deluca sold 6,427 shares of the stock in a transaction on Friday, August 9th. The stock was sold at an average price of $85.09, for a total transaction of $546,873.43. Following the completion of the sale, the executive vice president now owns 103,223 shares in the company, valued at approximately $8,783,245.07. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Robert M. Davis sold 216,718 shares of the stock in a transaction on Tuesday, June 25th. The shares were sold at an average price of $85.43, for a total value of $18,514,218.74. Following the sale, the chief financial officer now owns 354,378 shares of the company’s stock, valued at approximately $30,274,512.54. The disclosure for this sale can be found here. Corporate insiders own 0.27% of the company’s stock.

A number of hedge funds have recently modified their holdings of the stock. NewDay Solutions LLC purchased a new position in Merck & Co., Inc. in the 2nd quarter worth $240,000. Platinum Investment Management Ltd. raised its stake in Merck & Co., Inc. by 17.5% in the 2nd quarter. Platinum Investment Management Ltd. now owns 22,093 shares of the company’s stock worth $1,852,000 after acquiring an additional 3,293 shares during the last quarter. Prudential PLC raised its stake in Merck & Co., Inc. by 15.3% in the 2nd quarter. Prudential PLC now owns 2,712,247 shares of the company’s stock worth $227,467,000 after acquiring an additional 360,789 shares during the last quarter. TPI Fund Managers Ltd purchased a new position in Merck & Co., Inc. in the 2nd quarter worth $9,254,000. Finally, WealthStone Inc. purchased a new position in Merck & Co., Inc. in the 2nd quarter worth $586,000. Institutional investors own 75.34% of the company’s stock.

Merck & Co., Inc. Company Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Read More: How to Profit and Limit Losses With Stop Orders

Analyst Recommendations for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.